JP2010539152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539152A5 JP2010539152A5 JP2010524583A JP2010524583A JP2010539152A5 JP 2010539152 A5 JP2010539152 A5 JP 2010539152A5 JP 2010524583 A JP2010524583 A JP 2010524583A JP 2010524583 A JP2010524583 A JP 2010524583A JP 2010539152 A5 JP2010539152 A5 JP 2010539152A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidin
- isopropyl
- amino
- phenyl
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 14
- -1 3,3-difluoropyrrolidin-1-yl Chemical group 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 4
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 2
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- SLEQMPDPABSYDO-NIYFSFCBSA-N (1r)-2-(2,5-difluorophenyl)-1-[4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]ethanamine Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(=CC=2)[C@H](N)CC=2C(=CC=C(F)C=2)F)=N1 SLEQMPDPABSYDO-NIYFSFCBSA-N 0.000 claims 1
- WHYZGRKFZLNGSD-JTHBVZDNSA-N (2s)-1-[(2r)-2-amino-2-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]acetyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)[C@@H](N)C(=O)N3[C@@H](CCC3)C#N)CC2)=N1 WHYZGRKFZLNGSD-JTHBVZDNSA-N 0.000 claims 1
- ZQDWKPHJCXRHRB-WPWBMXPQSA-N (2s)-1-[(2s)-2-amino-2-[2-methyl-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]acetyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(C)C([C@H](N)C(=O)N3[C@@H](CCC3)C#N)=CC=2)=N1 ZQDWKPHJCXRHRB-WPWBMXPQSA-N 0.000 claims 1
- CZZMVEQIMKZLHY-ZHRMCQFGSA-N (2s)-1-[(2s)-2-amino-2-[4-[(3r)-3-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]acetyl]pyrrolidine-2-carbonitrile Chemical compound CCC1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(=CC=2)[C@H](N)C(=O)N2[C@@H](CCC2)C#N)=N1 CZZMVEQIMKZLHY-ZHRMCQFGSA-N 0.000 claims 1
- WHYZGRKFZLNGSD-GMAHTHKFSA-N (2s)-1-[(2s)-2-amino-2-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]acetyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)[C@H](N)C(=O)N3[C@@H](CCC3)C#N)CC2)=N1 WHYZGRKFZLNGSD-GMAHTHKFSA-N 0.000 claims 1
- CRCKCQCZRHPHLB-WPWBMXPQSA-N (2s)-1-[(2s)-2-amino-3-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(C[C@H](N)C(=O)N3[C@@H](CCC3)C#N)=CC=2)=N1 CRCKCQCZRHPHLB-WPWBMXPQSA-N 0.000 claims 1
- SUKKJMNNKVJEOR-URXFXBBRSA-N (2s)-1-[(2s)-2-amino-3-[2-fluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(C[C@H](N)C(=O)N4[C@@H](CCC4)C#N)=CC=3)CC2)=N1 SUKKJMNNKVJEOR-URXFXBBRSA-N 0.000 claims 1
- IOSAVHQKFCVJLD-ZCYQVOJMSA-N (2s)-1-[(2s)-2-amino-3-[2-methyl-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(C)C(C[C@H](N)C(=O)N4[C@@H](CCC4)C#N)=CC=3)CC2)=N1 IOSAVHQKFCVJLD-ZCYQVOJMSA-N 0.000 claims 1
- VCPNZKJRNBARFK-PBXXJUDPSA-N (2s)-1-[(2s)-2-amino-3-[4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(C[C@H](N)C(=O)N3[C@@H](CCC3)C#N)=CC=2)=N1 VCPNZKJRNBARFK-PBXXJUDPSA-N 0.000 claims 1
- OHKNZARUJPCXNB-UPVQGACJSA-N (2s)-1-[(2s)-2-amino-3-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(C[C@H](N)C(=O)N4[C@@H](CCC4)C#N)=CC=3)CC2)=N1 OHKNZARUJPCXNB-UPVQGACJSA-N 0.000 claims 1
- XVWDHSRRCPIECD-PSUQPPDWSA-N (2s)-1-[(3s)-7-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]pyrrolidine-2-carbonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C3CN[C@@H](CC3=CC=2)C(=O)N2[C@@H](CCC2)C#N)=N1 XVWDHSRRCPIECD-PSUQPPDWSA-N 0.000 claims 1
- YJGISLUOWUJJFW-VGSWGCGISA-N (2s)-2-amino-1-(3,3-difluoroazetidin-1-yl)-3-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(C[C@H](N)C(=O)N3CC(F)(F)C3)=CC=2)=N1 YJGISLUOWUJJFW-VGSWGCGISA-N 0.000 claims 1
- MEFDVHWWBOULGS-VGSWGCGISA-N (2s)-2-amino-1-(3,3-difluoropyrrolidin-1-yl)-2-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]ethanone Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C([C@H](N)C(=O)N3CC(F)(F)CC3)=CC=2)=N1 MEFDVHWWBOULGS-VGSWGCGISA-N 0.000 claims 1
- DQNIXQIIJJZWAN-JPYJTQIMSA-N (2s)-2-amino-1-(3,3-difluoropyrrolidin-1-yl)-3-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(C[C@H](N)C(=O)N3CC(F)(F)CC3)=CC=2)=N1 DQNIXQIIJJZWAN-JPYJTQIMSA-N 0.000 claims 1
- WTQXWLAPBPWHJR-GMAHTHKFSA-N (2s)-2-amino-1-[(3s)-3-fluoropyrrolidin-1-yl]-3-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(C[C@H](N)C(=O)N4C[C@@H](F)CC4)=CC=3)CC2)=N1 WTQXWLAPBPWHJR-GMAHTHKFSA-N 0.000 claims 1
- JUBCAZSGBFWUKJ-QFIPXVFZSA-N (2s)-2-amino-2-[2-fluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1-pyrrolidin-1-ylethanone Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C([C@H](N)C(=O)N4CCCC4)=CC=3)CC2)=N1 JUBCAZSGBFWUKJ-QFIPXVFZSA-N 0.000 claims 1
- VDVVGPKLUVPUDY-VGSWGCGISA-N (2s)-2-amino-2-[4-[(3r)-3-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]butoxy]phenyl]-1-(3,3-difluoropyrrolidin-1-yl)ethanone Chemical compound O=C([C@@H](N)C1=CC=C(C=C1)OCC[C@@H](C)C1CCN(CC1)C=1N=CC(Cl)=CN=1)N1CCC(F)(F)C1 VDVVGPKLUVPUDY-VGSWGCGISA-N 0.000 claims 1
- LUBOCGWFRWCWLP-JPYJTQIMSA-N (2s)-2-amino-3-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]-1-(1,3-thiazolidin-3-yl)propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(C[C@H](N)C(=O)N3CSCC3)=CC=2)=N1 LUBOCGWFRWCWLP-JPYJTQIMSA-N 0.000 claims 1
- IHXAHQDUBLZYBN-REWPJTCUSA-N (2s)-2-amino-3-[2-fluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1-[(3s)-3-fluoropyrrolidin-1-yl]propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(C[C@H](N)C(=O)N4C[C@@H](F)CC4)=CC=3)CC2)=N1 IHXAHQDUBLZYBN-REWPJTCUSA-N 0.000 claims 1
- UVHNVGBORWVEKJ-XXBNENTESA-N (2s)-2-amino-3-[4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]-1-(1,3-thiazolidin-3-yl)propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=CC(C[C@H](N)C(=O)N3CSCC3)=CC=2)=N1 UVHNVGBORWVEKJ-XXBNENTESA-N 0.000 claims 1
- QJSXQSGBVHJDAV-KOSHJBKYSA-N (2s)-2-amino-3-[4-[(4r)-4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]pentyl]-2-fluorophenyl]-1-(3,3-difluoropyrrolidin-1-yl)propan-1-one Chemical compound O=C([C@@H](N)CC1=CC=C(C=C1F)CCC[C@@H](C)C1CCN(CC1)C=1N=CC(Cl)=CN=1)N1CCC(F)(F)C1 QJSXQSGBVHJDAV-KOSHJBKYSA-N 0.000 claims 1
- QMRXJFRTDVYMRS-QFIPXVFZSA-N (2s)-2-amino-3-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1-(1,3-thiazolidin-3-yl)propan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(C[C@H](N)C(=O)N4CSCC4)=CC=3)CC2)=N1 QMRXJFRTDVYMRS-QFIPXVFZSA-N 0.000 claims 1
- LMYKXGHHUOFXRV-QHCPKHFHSA-N (2s)-2-amino-3-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1-pyrrolidin-1-ylpropan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(C[C@H](N)C(=O)N4CCCC4)=CC=3)CC2)=N1 LMYKXGHHUOFXRV-QHCPKHFHSA-N 0.000 claims 1
- RSLBXQOOWVXMME-IMWIBFENSA-N (2s,3s)-2-amino-1-(3,3-difluoropyrrolidin-1-yl)-3-[2-fluoro-4-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]phenyl]butan-1-one Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C([C@H](C)[C@H](N)C(=O)N3CC(F)(F)CC3)=CC=2)=N1 RSLBXQOOWVXMME-IMWIBFENSA-N 0.000 claims 1
- XOPQYBSLLCRCCY-DVECYGJZSA-N (3,3-difluoropyrrolidin-1-yl)-[(3s)-7-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]-1,2,3,4-tetrahydroisoquinolin-3-yl]methanone Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C3CN[C@@H](CC3=CC=2)C(=O)N2CC(F)(F)CC2)=N1 XOPQYBSLLCRCCY-DVECYGJZSA-N 0.000 claims 1
- NFWUMDGCOSUHFI-UHFFFAOYSA-N 2-amino-2-[4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1-pyrrolidin-1-ylethanone Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=CC(=CC=3)C(N)C(=O)N3CCCC3)CC2)=N1 NFWUMDGCOSUHFI-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
- XVMRINYOBITYOT-MBSDFSHPSA-N propan-2-yl 4-[3-[4-[(2s,3s)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-4-oxobutan-2-yl]-3-fluorophenoxy]propyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1CCCOC(C=C1F)=CC=C1[C@H](C)[C@H](N)C(=O)N1CC(F)(F)CC1 XVMRINYOBITYOT-MBSDFSHPSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0717568A GB0717568D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutic compounds |
| GB0717570A GB0717570D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutc compounds |
| GB0717569A GB0717569D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutic compounds |
| GB0717572A GB0717572D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutic compounds |
| GB0717571A GB0717571D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutic compounds |
| GB0717573A GB0717573D0 (en) | 2007-09-10 | 2007-09-10 | Therapeutic compounds |
| PCT/GB2008/050814 WO2009034388A1 (en) | 2007-09-10 | 2008-09-10 | Compounds for the treatment of metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539152A JP2010539152A (ja) | 2010-12-16 |
| JP2010539152A5 true JP2010539152A5 (show.php) | 2011-10-27 |
Family
ID=40292533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524583A Pending JP2010539152A (ja) | 2007-09-10 | 2008-09-10 | 代謝障害の治療のための化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100286112A1 (show.php) |
| EP (1) | EP2200609A1 (show.php) |
| JP (1) | JP2010539152A (show.php) |
| WO (1) | WO2009034388A1 (show.php) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| TW201111361A (en) | 2009-06-24 | 2011-04-01 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011019538A1 (en) | 2009-08-13 | 2011-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| US9499467B2 (en) | 2011-04-08 | 2016-11-22 | Caldan Therapeutics Limited | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
| US9181214B2 (en) | 2011-06-09 | 2015-11-10 | Rhizen Pharmaceuticals Sa | Bicyclic compounds as modulators of GPR-119 |
| EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| CA2855009C (en) | 2011-11-15 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| CA3156985A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| CN115667277A (zh) | 2020-02-28 | 2023-01-31 | 卡尔优普公司 | Gpr40激动剂 |
| EP4320129A1 (en) * | 2021-04-06 | 2024-02-14 | Kallyope, Inc. | Gpr119 agonists |
| CN117279889B (zh) * | 2022-04-28 | 2025-04-25 | 深圳湾实验室 | 经取代的氟硫酸盐及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| ZA977103B (en) | 1996-08-09 | 1999-02-08 | Eisai Co Ltd | Benzopiperidine derivatives |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| WO2000012704A2 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
| EP1122252A4 (en) * | 1998-10-16 | 2002-06-26 | Takeda Chemical Industries Ltd | CONDENSED HEREROCYCLIC NITROGEN COMPOUNDS; MANUFACTURING PROCESS AND AGENTS CONTAINING THEM |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| WO2001020995A1 (en) | 1999-09-23 | 2001-03-29 | Washington University | Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof |
| US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| US6528423B1 (en) * | 2001-10-26 | 2003-03-04 | Lsi Logic Corporation | Process for forming composite of barrier layers of dielectric material to inhibit migration of copper from copper metal interconnect of integrated circuit structure into adjacent layer of low k dielectric material |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用 |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US20100063081A1 (en) * | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| KR20080025190A (ko) | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | Ｇ-단백질 결합된 수용체 효능제 |
| JP2009532453A (ja) * | 2006-04-06 | 2009-09-10 | プロシディオン・リミテッド | ヘテロサイクリックｇｐｃｒアゴニスト |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| MX2009003823A (es) | 2006-11-02 | 2009-05-11 | Sanofi Aventis Deutschland | Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas. |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
| EP2377863A1 (en) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Piperidine GPCR agonists |
| GB0700122D0 (en) * | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
-
2008
- 2008-09-10 US US12/677,153 patent/US20100286112A1/en not_active Abandoned
- 2008-09-10 EP EP08806639A patent/EP2200609A1/en not_active Withdrawn
- 2008-09-10 WO PCT/GB2008/050814 patent/WO2009034388A1/en not_active Ceased
- 2008-09-10 JP JP2010524583A patent/JP2010539152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539152A5 (show.php) | ||
| JP2010506825A5 (show.php) | ||
| JP2009535346A5 (show.php) | ||
| JP2004529174A5 (show.php) | ||
| JP2007510713A5 (show.php) | ||
| JP2007520471A5 (show.php) | ||
| JP2011500659A5 (show.php) | ||
| RU2008136572A (ru) | Гетеробициклические сульфонамидные производные для лечения диабета | |
| JP2009519965A5 (show.php) | ||
| JP2006512357A5 (show.php) | ||
| JP2009525984A5 (show.php) | ||
| CA2607848A1 (en) | 3-substituted (3-phenyl)-propionic acid derivatives for the treatment of metabolic disorders | |
| JP2011507915A5 (show.php) | ||
| RU2002115263A (ru) | 5-членные N-гетероциклические соединения, обладающие гипогликемической и гиполипидемической активностью | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| JP2006500348A5 (show.php) | ||
| JP2008513515A5 (show.php) | ||
| CA2797767A1 (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| JP2015533157A5 (show.php) | ||
| JP2015509510A5 (show.php) | ||
| JP2013525262A5 (show.php) | ||
| JP2007511485A5 (show.php) | ||
| JP2013507366A5 (show.php) | ||
| CA2575081A1 (en) | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |